PDCD1 and hepatocellular carcinoma: Currently, the ICIs, such as anti-PD1 and anti-CTLA-4 antibodies, exhibit promising results in patients with advanced HCC; however, anti-PD-L1 antibodies are still under evaluation [14, 15].